Studies presented here show that some functions of the human herpesvirus, EBV, may be transcriptlonally differentially expressed in two cell types which carry the same (C15) Isolate of this virus. Of the 'latent' viral functions investigated, only one (TP2) of the episomally-speclflc genes that encode terminal proteins (TP1 and TP2) is found to be expressed In the C15 epithelial cell tumour environment, whereas both are transcribed-as different, but related, messengers-in a B-cell line generated with virus from the C15 tumour. The other gene investigated Is that for latent membrane protein (LMP), which is found in the same region of the EBV genome but on the opposite strand. This gene, apparently transcriptionally silent in B-cell (Burkitt's) lymphomas, is expressed in the C15 epithelial tumour, as well as in other nasopharyngeal carcinomas investigated. Promoter usage in the carcinomas and B-cells appears, In some cases at least, to be cell-type specific. Expression may also be governed by methylation since a chromosomally silent region In the carcinoma (that encompassing TP1) is highly methylated on CpG residues, whereas the active region (encoding TP2 and LMP) is virtually free of such methylation. Our data suggest that there may be selective transcriptional regulation of EBV genes in the two types of cells investigated. Thus, it may be unnecessary to invoke different virus genotypes to account for the two distinct malignancies-Burkitt's lymphoma and nasopharyngeal carcinoma-associated with EBV.
INTRODUCTION
One of the more unusual properties of the human herpesvirus, Epstein-Barr virus (or EBV), is the fact that it is associated with a variety of different diseases. These include infectious mononucleosis-where a causative role has been assigned-and tumours of both B-lymphocytes and epithelial cells (reviewed, ref. 1) . The best characterised of the B-cell malignancies is the common tumour of children in southern Africa, known as Burkitt's lymphoma (BL). In many Asian adult populations, EBV has been implicated in the genesis of a poorly differentiated carcinoma of the nasopharynx. The precise biology of EBV with regard to disease is uncertain, although it is clear from the above that the virus is able to infect and replicate in at least two distinct cell populations. Another feature of the EBV life cycle is also its ability to maintain a silent infection in its host, existing in a so-called 'latent state'; the precise site(s) of latency in vivo is as yet unknown. Description of latent gene expression has relied upon studies with B-lymphoblastoid cell lines, where a restricted set of EB viral genes encoding a number of nuclear proteins (EBNAs 1 -6) and three putative membrane proteins (LMP, TP1 and TP2), as well as two small RNA species (EBERs), are expressed (reviewed, ref. 2) . Numerous restriction enzyme analyses of EBV DNAs from various sources have been carried out in an attempt to determine whether genetic diversity among EB virions could account for the different host responses observed following infection with this virus (3, 4) . But, to date, there is no compelling evidence that this is the case. Although, not surprisingly for such a large virus (-175,000 base pairs), alterations are observed among viral genomes from different sources (5) , none of these have been directly related to the course of disease.
Several years ago we began to look into the likelihood that EBV gene expression in different cellular environments might vary and possibly be related to the pathologies associated with this virus. Our first studies on this topic showed that an area of EBV DNA not hitherto implicated in altering the properties of B-cells-contained within a cosmid recombinant DNA, p31-could induce cellular immortalization (continuous proliferation) of primary epithelial cells in culture (6, 7) . Then, in a comprehensive study of viral gene expression in a nasopharyngneal carcinoma (NPC) passaged in athymic mice, we observed that transcriptional expression in this tumour was markedly different from that previously reported for cell lines established from BL patients (8) . Similar results were obtained in biopsies from NPC patients (9) . In particular, high levels of transcription were observed from the region of EBV capable of in vitro immortalization of primary epithelial cells. We and others showed that CpG methylation patterns over the region implicated in expression of early viral nuclear antigens (EBNAs) also differed in the two cell types and might be responsible for, or at least related to, the observed differential gene expression (10, 11) . Here we have examined the transcription of part of the genome known to be involved in expression of a latent viral function(s)-initially designated terminal protein (or TP) (12)-in NPC tumours propagated in nude mice (13) , and compared the data with those obtained from a B-lymphoblastoid cell line generated from virus 'rescued' from one of these tumours (8, 14) and with expression of another function designated latent membrane protein (or LMP) which appears to be transcriptionally silent in Burkitt's lymphomas (1) .
TP is an unusual gene since, being encoded by information found in both extremes of a linearized viral genome (such as exists in EB virions), it can only be expressed off circular (episomal) forms of EBV or off tandemly repeated copies of the viral genome. (There is no evidence that the latter exist.) The structure of two TP transcripts has been elucidated (12, 15) and recently, two differently-sized TP proteins have been demonstrated to exist in B-cells (16, 17) . We have found the region encoding the TP gene to be transcriptionally active in the NPC tumours examined, as well as in a B-cell line established with rescued virus from one of the tumours. Our studies show that of the two TP transcripts observed in the B-cell environment, however, only one of them (TP2) is found in the carcinomas propagated in nude mice, even though the viral genome in the tumours is present as episomes and both promoters potentially are capable of being expressed. Further, differential expression can be shown to be correlated with methylation of one of the two promoter regions in the tumour. Investigation of the control of TP expression is complicated by the fact that the TP2 promoter region overlaps that of LMP, although the latter lies on the complementary DNA strand. The possible relationship between TP and LMP expression is discussed.
MATERIALS AND METHODS

Cells
C15 and C17 are human nasopharyngeal tumours of North African origin which have been passaged in nude mice (13, 18) ; NAD-C15-STO-B (hereafter referred to as NAD-C15) is a Blymphoblastoid cell line derived from co-cultivation of C15 cells with adult human B-cells (14, 19) , M-ABA is a lymphoblastoid cell line derived from an NPC patient, B95-8 is an EBV-infected marmoset cell line, permissive for viral replication, and Raji is an EBV positive Burkitt's lymphoma cell line. All cell lines were grown in RPMI1640 medium supplemented with 10% foetal calf serum and 2mM glutamine. Biopsies from nasopharyngeal carcinoma patients were obtained as described elsewhere (9) .
DNA clones
cDNA clones encoding TP were isolated from a C15 Xgt 10 cDNA library (8) . Recombinant plaques were screened as previously described (8); plaques positive when probed with the EBV EcoRl I fragment (20) were subcloned and sequenced according to standard protocols.
RNA extraction and Northern blotting
Total RNA was isolated by the guanidinium/caesium chloride method (21) . Poly(A) + RNA was selected by chromatography on two sequential oligo (dT)-cellulose columns (Pharmacia) as described by the manufacturer. For Northern blotting analysis, poly A + RNA (5/ig) was loaded in each lane of a 1 % agarose gel containing 0.7 % formaldehyde and 5mM iodoacetamide, and subjected to electrophoresis. RNA was transferred to Zetaprobe membrane (Bio-Rad) by capillary transfer and all subsequent hybridization steps performed according to the manufacturers' instructions. DNA used to probe Northern blots was labelled using the Amersham multiprime kit (Amersham pic).
Oligonucleotides for Polymerase Chain Reaction (PCR)
A shared TP1/TP2 20-long oligonucleotide (TP1,2-R) 5'-TTT-CCTTTGTGCAGCGGCAT (from exon 2 of the TP genes), position 232-212 on the EBV B95-8 genome (22) , and specific oligonucleotides for TP2 (exon 1) 5'-AGCGGCAGTGTAAT-CTGCAC (designated TP2-L), position 169819-169839 and for TP1 (exon 1) 5'-CGCCTTATGAGGACCCATAT (designated TP1-L), position 166739, were synthesised using an Applied Biosystems oligonucleotide synthesizer. With these oligonucleotides, the predicted sizes of the PCR products from the respective mRNAs should be 351 bp for TP1 and 264 for TP2. Oligonucleotides used for PCR of LMP were synthesised from exon a, 5'-CTTGTCCTCTATTCCTTTGCT, position 169318 to 169297, and from exon c, 5'-GTCTGCCCTCGGT-TGGAGT, position 168651 to 168638; these should result in a PCR fragment of 513 bp if derived from spliced mRNA or 680bp if from unspliced RNA or DNA (23) .
PCR
Oligonucleotide TP1.2-R was hybridised to poly A + RNA (1/ig) in a volume of 20/il containing 2/xl of 10 x reverse transcriptase buffer (250mM Tris/HCl pH 8.3, 25mM MgCl 2 , 1.25mM of each deoxynucleotide dATP, TTP, dCTP, dGTP, 20mM DTT and lOOmM KC1), and 10 units of RNasin (Promega). Hybridization was carried out at 60 °C for 20 minutes and the reaction cooled in ice for 2' prior to the addition of 12 units of reverse transcriptase. The resulting solution was incubated at 37°C for 60 minutes. The cDNA generated was divided into two aliquots and the oligonucleotides TP1-L and TP2-L, specific for TP1 and TP2 transcripts, respectively, were used in conjunction with the common primer TP1.2-R, to amplify specific products. PCR analyses were performed in a volume of 50/tl containing 10/xl cDNA, 5/*l 10X reaction buffer (200mM Tris/HCl pH 8.3, 15mM MgCl 2 , 25OmM KC1, 200/iM of each dNTP) and 5 units Taq polymerase. The PCR conditions used were 94°C for 30 seconds, 55°C for 30 seconds and 72°C for 2 minutes, over 30 cycles. PCR generated products were separated by electrophoresis on a 1.2% agarose gel, transferred to Bio-dyne paper and probed at 60°C for 20' using standard methods.
Analysis of DNA methylation
Total cellular DNA was digested with either HpaU or its methylation insensitive isoschizomer, Mspl, as described (10) . In each case 20/ig of total cellular DNA was digested overnight with lOunits enzyme//ig DNA. The digested DNA was separated on a 1.2% agarose gel and transferred to nitrocellulose by capillary transfer. The filters were then hybridised with 32 P labelled DNA probes corresponding to the putative promoters for the two terminal proteins. For analysis of the TP1 promoter, a fragment with co-ordinates 166075-166502 from the EBV genome was used as a probe, and for TP2 from 169477 -169848 (22) . The probes were generated by PCR from C15 tumour DNA.
RESULTS
Two transcripts have been identified with the expression of terminal proteins. Data on these are summarised in Figure 1 and are derived from previously published observations in B-cells (12, 15) and, in part, from our own studies with the C15 NPC tumour (below). The transcripts use different promoters at the 'right hand' end of the conventionally-orientated EBV genome, as shown ( Figure 1 ) and their first exons (exons 1) are not shared. In TP2, this exon is non-coding. The two transcripts, on the other hand, have identical 3'-exons (exons 2-9).
Analysis of cDNA clones isolated from a C15 XgtlO cDNA library (8) showed sequences from both extremes of a linearised EBV genome-such as would be found in virions-to be present. Since no linear forms of the DNA exist in the tumour, an obvious explanation for the hybridization data was that TP transcripts spanning the ends were being transcriptionally expressed. Putative TP clones were therefore identified in the library by filter hybridization and the primary sequences of five of them were determined (24) . [The only sequence alteration identified in the C15 clones, relative to that of the prototype B95-8 isolate DNA (22) , involved a base change at position 78 in exon 2, which would result in a change from CCT (proline) to CTT (leucine) in a translation product.] The sequence data (not given) showed all of them to be consistent with the presence of only one of the two known transcripts of TP, that is, with the TP2 transcript ( Figure 1 ). Of the five clones, three were spliced from the TP2 exon 1 region. The other two which contained exons from the 3' region of the transcript were unspliced 5' to exon 2. This could reflect the usage of an alternative (third) promoter, but most likely is a result of some unspliced mRNAs in the library, as noted earlier (8) . No full-sized cDNA clones were isolated in this study; the largest clone analysed (designated D5) was 960bp and consisted of a sequence whose 5' end was in exon 1 of TP2 and whose 3' end was in exon 6 (see Figure 1 ). These findings suggested that in the tumour either the region unique to TPl is transcriptionally silent or that the TP2 transcript is considerably more abundant than that of TPl.
RNA extraction and Northern blotting
Northern blot analyses were carried out using (polyA + ) mRNA from the C15 tumour and, as probe, the D5 cDNA clone (above). The data have been compared with results obtained using several well-characterised EBV-positive B-cell lines, including the line, NAD-C15, established from virus induced from the C15 tumour. The results obtained are shown in Figure 2 . In summary, in all the B-cells analyzed-except Raji (track B) which has a deletion that precludes expression of TPl transcripts (12; see Figure 1 )-two TP transcripts were found. Quantitatively, however, no consistent pattern was observed in B-cells. In some (see tracks C and D, Figure 2 ) the most prominent RNA was the larger of the two transcripts (corresponding to TPl, about 2.0 kb in length), whereas in others, the smaller transcript (TP2, about 1.7 kb) was the more prominent (see track A, Figure 2 ). In the nude mouse tumours, C15 (track E), as in Raji cells, on the other hand, only the TP2 transcript was observed.
PCR Analysis
The failure to find TPl transcripts in C15 (or the other NPC propagated in nude mice, C17) by Northern blot analyses, or in a cDNA library, might be a genuine result or merely reflect the fact that this message is one of very low abundance. Therefore, PCR was utilised to assess whether there was low level expression of TPl in the tumour. The data obtained, as given in Figure 3 , complement those obtained by the other methods, however. That is, the B-cell lines, B95-8 (panels B, lanes 2 and 1) and NAD-C15 (panels D), show bands derived from both sets of oligonucleotide primers, whereas Raji (panels C) and C15 (panels A) or C17 (not shown) gave a single band, corresponding to the use of an oligonucleotide specific for an exon from TP2 but not to one using sequence from a specific exon in TPl. Similar data were also obtained with mRNA of one biopsy from a nasopharnygeal carcinoma patient from Hong Kong. This was not the case with three other biopsies, however, where both TPl and TP2 products were identified (data not given). [The data on primary NPC biopsies cannot be assumed to represent expression in epithelial cells, however, since these tumours (often referred to as lymphoepitheliomas) contain numerous invasive lymphocytes, some of which could be EBV-positive Blymphocytes]. No PCR products were obtained in the control (the EBV negative B-cell line, Ramos) with either set of oligomers.
Restriction Enzyme Digestions
The simplest explanation for lack of TPl expression in C15 or other tumours is that-similar to the situation observed in Raji cells-a deletion is present in the viral genome which precludes synthesis of TPl. Restriction enzyme analyses carried out on total chromosomal DNA from C15 and probed with viral sequences corresponding to those deleted in Raji (see Figure 1 ) indicated, however, that there was no gross deletion in the C15 tumour in this region of the genome to account for the experimental observations (data not shown). These findings are consistent, moreover, with the fact that the NAD-C15 cells, derived from virus 'rescued' from C15, express both TPl and TP2 transcripts.
[Whereas it is conceivable that the EBV genome in NAD-C15 is different from that in C15, this seems unlikely since sequencing of other areas of the genomes, including that of a known highly polymorphic region of EBV encoding the nuclear antigen EBNA-1 (9, and our unpublished work), has showed the two DNAs to be indistinguishable.]
Methylation of TPl and TP2 promoter regions
An alternative explanation for the failure of TPl transcription is that the corresponding promoter is transcriptionally silent in the tumours. Earlier studies had shown tumour DNA to be highly methylated in viral regions encoding promoters for some EBV genes (notably EBNAs 2-6) (10, 11, 19) . Methylation of CpG residues in promoter regions has often been associated with a failure of these regions to be transcribed (25, 26) . Therefore, utilisation of methylation sensitive and insensitive isoschizomers, such as HpaU (sensitive) and Msp I (insensitive), should give data concerning the methylation status of promoter regions and an indication of the 'transcriptional status' of these promoters. To assess methylation of TPl and TP2 promoter regions among the various cells under investigation, chromosomal DNAs from several of them were cleaved with this isoschizomer restriction enzyme pair. Figure 4 shows the theoretical MspVHpaU map of both the TPl and TP2 promoter regions: use of TPl and TP2 promoter specific probes, as indicated in the figure, should identify fragments of 818 and r64bp in the TPl promoter region and 146, 107 and 504bp in the TP2 promoter regions, respectively (23), assuming complete enzymatic digestion. Figure 5 shows the actual results obtained after probing one digest. With a probe for the promoter region of TPl (Figure 4 , panel A), both B95-8 and NAD-C15 were cleaved to give an 818bp fragment, indicative of complete digestion with HpaU and no methylation at CpG sites within this region. In contrast, with C15 tumour DNA, the corresponding probe recognised only a very large (> 10kb) fragment, indicative of extensive CpG methylation. To confirm that incomplete digestion with HpaU could not account for the results obtained, the experiment was repeated, using an independently isolated sample of C15 DNA and a different batch of HpaU enzyme. Identical results were obtained (not given).
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|-«513bp Figure 6 . PCR amplification of LMP transcripts. As in Figure 3 ; primers were chosen to amplify mRNAs corresponding to 513bp of LMP transcripts. (Poly A + ) RNA was derived from NPC patient biopsy materials (tracks 1-7), from two NPC biopsies passaged in nude mice, C17 and C15 (13) and from the EBV negative B-cell line, Ramos. When the probe used corresponded to the TP2 promoter region (panel B) more or less complete digestion of the DNA with both enzymes was observed in all three cell lines investigated, implying little or no CpG methylation in this region of the genome. The results are consistent with the findings regarding transcription in the tumours, as compared with the B cell lines.
Transcriptional Expression of LMP
A second viral transcript, that for a membrane-associated latent protein (LMP; 23), has been identified in the TP1/TP2 promoter region of the EBV genome (see Figure 1) . But, whereas TP1 and TP2 are transcribed in a 'rightward' direction, LMP is transcribed 'leftward' from the opposite strand. To confirm that the latter region was transcriptionally active in the NPCs, the ability of the LMP gene to be transcribed was investigated. This seemed especially relevant since Western blot analyses using sera from NPC patients have suggested that the LMP protein is expressed in only about 30-65% of NPC biopsies examined (14, 27) . We have used PCR to assess the presence of the LMP transcripts in the C15 tumour, as well as in a variety of samples from NPC patients. The findings are shown in Figure 6 . Although ours is a limited study-due to the paucity of available biopsy materials-without exception all the isolates examined were
DISCUSSION
The terminal protein (TP) genes-TP1 and TP2-encoded by the fused terminal repeats of the viral genome prove to be an instructive model for studying control of viral gene expression in EBV-carrying cells. Although biological functions for these two related genes have not yet been identified, they use different promoters and specify differently-sized (40 and 53kD) proteins (16, 17) . Presumably these proteins have different activities. In EBV positive B-lymphoblast cell lines, several studies have shown both viral genes to be transcriptionally expressed (12, 15) . Our hybridization studies on a cDNA library derived from the C15 NPC tumour further suggested that TP was transcriptionally active in carcinoma cells as well as in B-cells (8) . Subsequent sequence analysis of a number of clones in the library confirmed this, but failed to reveal any that would correspond to the larger of the two TP transcripts, that for TP1; all clones analysed were derived from TP2 transcripts. A variety of different experiments were therefore carried out to investigate whether TP1 was indeed transcriptionally silent in the tumour or whether there might be a trivial technical explanation for this observation. All methods used confirmed, however, that the TP1 gene was silent in the NPC C15 tumour investigated, although it was transcriptionally expressed in a complimentary B-cell line (NAD-C15) derived from virus 'induced' from this same tumour. The TP1 gene transcript was also found to be absent (by PCR) in the C17 NPC tumour (13) , propagated in nude mice. As a corollary to these experiments, the transcriptional expression of a membrane protein, designated latent membrane protein, (or LMP), encoded within the same area of the EBV genome but from the strand complementary to that encoding TP genes (Figure 1) , has also been investigated in the C15 tumour, as well as in C17 and a number of biopsies from NPC patients. Transcriptional expression of LMP was identified by PCR in 100% of the NPC tumours studied. The TP2 gene was also transcriptionally expressed in all cells examined.
It is outside the focus of this paper to dwell in depth on the putative role(s) of EBV genes in tumour formation. However, it is noteworthy that LMP has been identified as a transforming oncogene in in vitro experiments and that the transformed cells produce tumours in immunodeficient (nude) mice (28) . Thus, whereas there may be no a priori reason why TP genes need be expressed in tumour cells, because of the juxtaposition of the promoters for LMP and TP2, if LMP expression is essential for the initiation or maintenance of a carcinoma (ie, NPQ, this region of EBV-which also includes the promoter for the TP2 genemust be transcriptionally active. The fact that the other TP gene, TP1, is not always expressed suggests that this gene may not be involved in the tumorigenesis process. If this hypothesis is correct, and if LMP expression is not required in the case of Burkitt's lymphomas (1), one would predict that TP gene expression might also be silent in these tumours. To our knowledge, this has not yet been explored. Again, as we (10) and others (11) have shown earlier, CpG methylation appears to play a key role in producing, or maintaining, transcriptionally silent regions of the viral genome in EBV-associated tumours: A probe containing the TP1 promoter sequence (Figure 4 ) identifies no HpaD. sensitive sites over a region in excess of lOkbp in the C15 tumour, in a region of the viral genome where there are numerous restriction sites, a number of which are shown. Indeed, these data would suggest that virtually no promoter in the region of the EBV genome immediately 5' to the TP1 genome, contained within the BamHl A (12kbp) restriction fragment of the genome, would be transcriptionally active. Notably, this region contains a number of genes, including the viral DNA polymerase, associated with either replication or encapsidation (29) and our earlier data showed them to be transcriptionally silent in the tumour (8) . The most compelling conclusion allowed by data obtained in this study is that relating to promoter usage and possible cellular control over transcriptional expression of viral genes. Thus, differential transcriptional expression within a host cell may be sufficient to account for the varying pathologies associated with viral infection for a multigene virus like EBV.
